Radiopharmaceutical Sciences
A section of Pharmaceuticals (ISSN 1424-8247).
Section Information
The aim of Radiopharmaceutical Sciences section of the journal is to provide academic and industrial communities with open access to publications on development of primarily novel radiopharmaceuticals and their application for fundamental and applied studies in biology and medicine. The development of the radiopharmaceuticals considers the design, synthesis and radiolabeling of the agents, their biological and preclinical evaluation, and finally clinical application. Contributions may concern targeted, pre-targeted, and non-targeted radiopharmaceuticals ranging from small molecules via peptides, peptidomimetics and antibodies and derivatives thereof to particles for their use in gamma scintigraphy including single photon emission tomography (SPECT), positron emission tomography (PET) and endoradiotherapy. The field of diagnostic imaging and (radio)pharmaceutical therapy guided by the diagnostic imaging is of strong interest. The related topics of physics, dosimetry, radiopharmacy, and hybrid imaging are also accepted. Download Section Flyer
Keywords
- Radiopharmaceuticals, agents, probes
- Radionuclides
- Imaging biomarkers
- Biological/preclinical evaluation
- First in-human clinical studies
- SPECT, PET/CT, PET/MRI
- Labeling chemistry
- Medicinal radiochemistry, (pre)clinical radiopharmacology, and radiopharmacy including GMP-compliant production
- Radiopharmaceutical drug development
- Radiotheranostics
- Hybrid imaging
- Organic molecules, high-molecular weight biomolecules, nano- and microparticles
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Radiolabeled Nanoparticles for Diagnosis and Therapy (Deadline: 20 June 2023)
- Tumor-Targeting Radioligands for Molecular Imaging and Therapy (Deadline: 30 June 2023)
- Automation of Radiolabeling Processes (Deadline: 1 August 2023)
- In Vivo Nuclear Molecular Imaging in Drug Development and Pharmacological Research 2023 (Deadline: 20 August 2023)
- Alliance of PET/SPECT Imaging and Drug Design/Discovery for the Development of Novel Diagnostic or Therapeutic Tools (Deadline: 31 August 2023)
- Feature Reviews in Radiopharmaceutical Sciences: Highlights of Two-Decade Development (Deadline: 15 September 2023)
- Application of Radiolabeled Agents: Imaging, Therapy, Multimodal Approaches and Beyond (Deadline: 15 September 2023)
- Gallium 68 Radiochemistry and Labelling Strategies (Deadline: 25 September 2023)
- Targeted Alpha Therapy (TAT): Progress in Radionuclide Production, Radiochemistry and Applications (Deadline: 29 September 2023)
- Radiopharmaceuticals and Sarcopenia (Deadline: 30 September 2023)
- New Trends in Applications and Production of Metal Radionuclides for Nuclear Medicine (Deadline: 20 October 2023)
- Therapeutic Radionuclides in Nuclear Medicine (Deadline: 31 October 2023)
- Antibody-Based Imaging and Targeted Therapy in Cancer (Deadline: 30 November 2023)
- Development of Novel Radiotracers for PET Imaging (Deadline: 31 December 2023)
- Copper Radiopharmaceuticals for Theranostic Applications (Deadline: 31 December 2023)
- Radiopharmaceuticals and Nanotechnology (Deadline: 31 January 2024)
- 20th Anniversary of Pharmaceuticals–Advances in Radiopharmaceutical Sciences and Nuclear Medicine (Deadline: 20 June 2024)
